Preparation and Biological Evaluation of Iodopromazine as a Radiopharmaceutical Model for Brain Imaging | ||||
| Benha Journal of Applied Sciences | ||||
| Article 36, Volume 6, Issue 1, January and February 2021, Page 231-236 PDF (544 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2021.169114 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| M.A. Motaleb1; A.M. Othman2; I.T. Ibrahim1; M.E. Moustafa3 | ||||
| 1Hot Lab.Center, Atomic Energy Authority,Cairo, Egypt | ||||
| 2Egypt Second Research Reactor, Atomic Energy Authority,Cairo,Egypt | ||||
| 3Chem Dept.,Faculty of Sciences, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| This study aimed to prepare a novel radiopharmaceutical for the detection of brain disorders at early stages in susceptible patients.Promazine hydrochloride was labeled with 125I by direct electrophilic substitution reaction with high labeling yields of 92.6 ± 3.24 %. The labeling yield and in vitro stability of 125I-promazine were determined by paper electrophoresis, paper chromatography (PC) and High performance liquid chromatography (HPLC). In vitro studies showed that the highest radiochemical yield of 125I-promazine (92.6±3.24%) was stable up to 6 h. Biodistribution studies showed that maximum uptakes of 125I-promazine in the brain of mice was 5.4 ± 0.18 % injected dose/g after 30 min post-injectionwhich is higher than that of 99mTc-HMPAO and 99mTc-ECD (2.25 and 4.7 %, respectively), so this confirms the high specificity and selectivity of this radiotracer for brain and could be used for brain imaging instead of the commercially available 99mTc-HMPAOand 99mTc-ECD. | ||||
| Keywords | ||||
| 125I-promazine hydrochloride (PMZ); Brain imaging; Electrophilic substitution; Radioiodination | ||||
|
Statistics Article View: 118 PDF Download: 300 |
||||
